213 results
8-K
EX-99.1
WINT
Windtree Therapeutics Inc
26 Feb 10
Discovery Labs Announces Completion of
12:00am
products, or other companies may develop competing therapies and/or technologies, or health care reform may adversely affect Discovery Labs; risks … of legal proceedings, including securities actions and product liability claims; risks relating to health care reform; and other risks and uncertainties
8-K
EX-99.1
WINT
Windtree Therapeutics Inc
18 Feb 10
Discovery Labs Prices $16.5 Million Public Offering of
12:00am
companies may develop competing therapies and/or technologies, or health care reform may adversely affect Discovery Labs; risks of legal proceedings … , including securities actions and product liability claims; risks relating to health care reform; and other risks and uncertainties described in Discovery Labs
8-K
EX-99.1
WINT
Windtree Therapeutics Inc
19 Aug 09
Discovery Labs Announces Resignation of CEO Robert J. Capetola, Ph.D.; W. Thomas Amick, Chairman of the Board, Appointed Interim CEO
12:00am
the patents and licenses related to its products, or other companies may develop competing therapies and/or technologies, or health care reform may … and health care reform; and other risks and uncertainties described in Discovery Labs’ filings with the Securities and Exchange Commission including
8-K
EX-99.1
WINT
Windtree Therapeutics Inc
17 Jun 10
Discovery Labs Prices $10.0 Million Public Offering of
12:00am
competing therapies and/or technologies, or health care reform may adversely affect Discovery Labs; risks of legal proceedings, including securities … actions and product liability claims; risks relating to health care reform; and other risks and uncertainties described in Discovery Labs’ filings
8-K
EX-99.1
WINT
Windtree Therapeutics Inc
8 May 09
Discovery Labs to Raise $11.3 Million in Registered Direct Offering
12:00am
and protect the patents and licenses related to its products, or other companies may develop competing therapies and/or technologies, or health care reform … to reimbursement and health care reform; and other risks and uncertainties described in Discovery Labs’ filings with the Securities and Exchange Commission
8-K
EX-99.1
m1ekl6niv04ccn2zo
8 Nov 12
Discovery Labs Reports Third Quarter 2012 Financial Results
12:00am
8-K
EX-99.1
rkvd ldzky24q
11 Sep 09
Other Events
12:00am
8-K
EX-99.1
9illu7 qv003gt
4 Dec 09
Discovery Labs Receives Nasdaq Notification Related
12:00am
8-K
EX-99.1
lpepcae3
14 Jun 10
Discovery Labs Secures $35 Million Committed Equity Financing Facility
12:00am
8-K
EX-99.1
0knequv2ackb2 hbt27
4 Jun 10
Discovery Labs Announces Listing Transfer to NASDAQ Capital Market
12:00am
8-K
EX-99.1
noc 1i41b
4 Sep 09
Discovery Labs Announces Date of 2009 Annual Shareholder Meeting
12:00am
D
557k2dkoy lusammn
19 Dec 19
$26.42M in equity / options, sold $26.42M, 5 investors
4:30pm
D
oggef
25 Jul 18
$1.5M in options, sold $1.5M, 1 investor
2:59pm
8-K
EX-99.1
n3z2joc i4w6t
12 May 09
Other Events
12:00am
8-K
EX-99.1
xisbdqas
9 Jun 10
Discovery Labs Reports Preliminary Results from Phase 2 Clinical Trial of Surfaxin in Pediatric Acute Respiratory Failure
12:00am
8-K
EX-99.1
i99xvziq z2
13 Oct 10
Entry into a Material Definitive Agreement
12:00am
8-K
EX-99.1
67im24gjwdl9tn
29 Apr 09
Discovery Labs Reports First Quarter 2009 Financial Results
12:00am
D
z7x7jw
7 Jun 13
$12K in equity, sold $12K, 1 investor
12:00am
8-K
EX-99.1
bhoybutffziix6
21 May 10
Discovery Labs Achieves Key Milestone Towards Potential Surfaxin® Approval
12:00am
D
ltk 2wjy45yjnbt6q7
15 Mar 13
$18.45K in equity, sold $18.45K, 1 investor
12:00am